Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Not yet recruiting

• Conditions: Hypertrophic Cardiomyopathy (HCM)
• Interventions: Diagnostic Test: myocardial contrast echo

• Registration Number: NCT06599229
• Lead Sponsor: University of Virginia

Brief Summary

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-09-13
• Study First Submitted QC: 2024-09-13
• Last Update Submitted: 2024-09-13
• Study First Posted: 2024-09-19
• Last Update Posted: 2024-09-19
• Study Start: 2024-11-15
• Primary Completion: 2027-12-01
• Study Completion: 2028-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Diagnosis of hypertrophic cardiomyopathy
• Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

Exclusion Criteria

• Pregnancy
• Lactation
• Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
• Serious AE to regadenoson
• Hypotension
• Serious bradycardia not addressed by pacemaker
• Moderate or greater reactive airways disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with HCM initiated on cardiac myosin inhibitor therapy	myocardial contrast echo	Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.

Primary Outcome Measures

Name	Time	Method
Peak hyperemic perfusion	3 months	Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)

Secondary Outcome Measures

Name	Time	Method
Resting myocardial perfusion	3 months	Resting myocardial perfusion by MCE